Compare Sea Limited (SE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Sea Limited (SE) trades at $114.80, up 1.21% with strong technical momentum as the stock approaches key resistance levels. The company demonstrates robust fundamental growth with Q2 2026 revenue of $7.8 billion (up 48% YoY) and net income growth of 11%, supported by diversified performance across e-commerce, fintech, and gaming segments. Analyst consensus remains strongly bullish with a $128.33 price target, though valuation metrics appear elevated with a P/E of 50.78.

SE presents compelling growth prospects with accelerating revenue and expanding profitability, but faces risks from increased investment spending and competitive pressures. The stock's current technical overbought condition near resistance suggests potential near-term consolidation before further upside. Wall Street's overwhelming buy rating (70% of analysts) supports the positive long-term outlook despite premium valuation concerns.

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.